Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorBeth Israel Deaconess Medical Center

About this trial

This study is testing whether a short, daily, app-based meditation can help young adults feel better in their everyday lives.

We will invite about 354 adults between 18 and 40 years old who live in the United States to join.

Everyone who joins will be randomly placed into one of three groups for 4 weeks: Intervention group will do a 7-minute Miracle of Mind meditation each day using a phone app. Active comparator group will listen to a neutral 7-minute audio lesson each day. Control group will continue their usual daily routine without adding anything new.

All participants will answer short online surveys at the start and several times during the 4 weeks, sharing how they feel about their mood, stress, anxiety, overall well-being, and mindfulness.

Participants who already wear a smartwatch (like a Fitbit or Apple Watch) can choose to share their heart rate-related data so we can see whether the meditation might also affect physical signs of stress.

Investigators will compare how participants in the three groups change over time to see if the daily 7-minute meditation helps young adults feel better, less stressed, and more emotionally resilient.

Eligibility criteria

Qualifiers

Individuals between the ages of 18-40 years

Currently residing in the USA

Individuals who are English speaking

Willing and able to download an application on iOS/Android

Disqualifiers

Individuals who are non-English speaking

Unable to access an iOS/Android smartphone

Individuals who regularly practice any form of meditation >4 times per week

Individuals scoring 9-12 on the PHQ-4, or ≥3 on either the PHQ-2 or GAD-2 subscale

Trial design

Treatments tested in this trial

  • Miracle of Mind meditation
  • Neutral audio learning task

Treatment groups

354 Participants
are divided into 3 treatment groups

Locations

This trial has no locations